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Background: Reperfusion of large vessel occlusions in acute stroke can improve patient outcomes. The purposes of this study
were to assess the safety and efficacy of the Penumbra 5MAX ACE catheter for revascularization of large vessels and to compare
its cost to the cost of stent retrievers.
Methods: In this retrospective, single-center case review study, data were captured on consecutive patients treated with the
Penumbra 5MAX ACE as first-line therapy during an 11-month period. Good functional outcome was defined as a modified
Rankin Scale score of 2 at discharge. Results were directly compared with previously published data for stent retrievers, and
length of stay was analyzed in relation to revascularization.
Results: The 31 patients studied had a mean age of 66.3 – 17.8 years and a mean National Institutes of Health Stroke Scale
score of 19.4 – 5.7. Intravenous tissue recombinant plasminogen activator therapy was initiated in 35.5% (11/31) of patients. A
Thrombolysis in Cerebral Infarction (TICI) grade of 2b-3 reperfusion after endovascular therapy was achieved in 26/31 (83.9%) of
cases; TICI grade 3 was achieved in 19/31 (61.3%) patients. The average time from groin puncture to TICI grade 2b-3 reperfusion
was 40 minutes. The average estimated cost for aspiration with the 5MAX ACE alone was $4,916 per case compared with an
estimated cost of $9,620 if a stent retriever was used as the primary device. Our actual average cost per case, including all
adjunctive devices used in the neurointerventional procedure, was $6,997. Good functional outcome was achieved in 19/31
(61.3%) patients. Two patients experienced symptomatic intracerebral hemorrhage (6.5%), and 1 (3.2%) patient died. The length
of stay was significantly shorter among patients with TICI grade 2b-3 reperfusion compared to patients with TICI grade <2 (6.8
– 5.34 days vs 15.8 – 11.32 days, respectively; P<0.05).
Conclusion: These findings suggest that direct aspiration with the large-bore 5MAX ACE catheter can be considered a first-line
approach to mechanical thrombectomy for large vessel occlusions. Our results demonstrated high rates of successful
reperfusion in a timely manner with excellent clinical outcomes, although our sample size was small. In addition, this direct-
aspiration technique has important cost-savings potential compared to stent retrievers.
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INTRODUCTION
Acute ischemic stroke is the fourth leading cause of death
in the United States and is also the leading cause of long-
term disability in the country.1,2 Strokes attributable to large
vessel occlusion or proximal vessel occlusion have a poor
prognosis if allowed to follow their natural course, but with
early revascularization treatment, patient outcomes have
improved and mortality has decreased.3,4 Much has been
published about the advances in techniques for mechanical
approaches to revascularization of large vessel occlusion,5,6
and in 2015, intraarterial treatment to achieve revasculari-
zation was demonstrated to be safe while improving
outcomes.7 The purpose of this study was to assess the
safety and effectiveness of achieving revascularization of
proximal or large vessel occlusion using the Penumbra
5MAX ACE catheter with ADAPT (A Direct Aspiration First
Pass Technique). Also, because care must be provided in a
cost-effective manner in today’s medical environment, we
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also compared the cost of the Penumbra 5MAX ACE
catheter with the cost of stent retrievers.
METHODS
A retrospective review of the medical records from
September 2013 to July 2014 was conducted of all patients
with large vessel occlusion strokes who were treated with
mechanical thrombectomy using ADAPT and the recently
introduced (June 2013) 5MAX ACE catheter (Penumbra,
Inc.) as first-line therapy. Patient selection for endovascular
treatment of large vessel occlusion acute stroke at our
institution is based on noncontrast computed tomography
(CT), CT angiogram, and whole brain 320-slice CT perfusion
imaging, regardless of time of onset. This study was
conducted after institutional review board approval, and
informed consent was obtained from patients or their legal
representatives in accordance with the Helsinki Declaration
of 1975, as revised in 2005.
Data on age, sex, and presentation National Institutes of
Health Stroke Scale (NIHSS) score were recorded. The
NIHSS lists 11 specific abilities that are scored on numerical
scales, with 0 indicating normal function and higher scores
indicating some level of impairment. The maximum possible
score is 42, and the minimum score is 0. Groin puncture
time, reperfusion time, Thrombolysis in Cerebral Infarction
(TICI) grade flow before and after the procedure, and
procedural complications were also recorded. The TICI
grading system is a tool for determining the response to
thrombolytic therapy for ischemic stroke. The grades range
from 0 (no perfusion) to 3 (complete perfusion). TICI
subcategory grade 2b indicates complete filling of all of
the expected vascular territory but with slower than normal
filling. Follow-up data in the form of the modified Rankin
Scale (mRS) score at discharge was also obtained from the
medical records. The mRS is used to measure the degree of
disability in carrying out daily activities for people who have
had a stroke or have some other neurological disability. The
scale is scored from 0 (no disability) to 6 (death). Higher
scores indicate greater disability.
Thrombectomy cases using ADAPT with the 5MAX ACE
were selected based on vessel size and the intervention-
alist’s opinion that the catheter was the proper size for the
occluded vessel. Patients with distal lesions (M2 or further)
or with small caliber proximal vessels for which the 5MAX
ACE was considered too large were not treated with the
device, and hence, are not included in this discussion.
However, all patients in whom the following technique
was used during the specified time frame are included in the
study cohort. The technique involves an 8 French groin
sheath through which a NeuronMAX 088 access catheter
(Penumbra, Inc.) is advanced over a Davis diagnostic
catheter (Torcon NB Advantage Catheter; Cook Medical)
and an angled Glidewire (Terumo) into the internal carotid
or vertebral artery of the affected side. Once in position, the
5MAX ACE aspiration catheter is advanced to the proximal
segment of the thrombus with the aid of either a 3MAX
aspiration catheter or a Velocity microcatheter (Penumbra,
Inc.) with the support of a Fathom microwire (Boston
Scientific Corporation). Whether to use a 3MAX or a Velocity
microcatheter was the operator’s decision (twice the 5MAX
ACE was advanced over a Fathom microwire alone). Direct
aspiration using the Penumbra reperfusion system (ADAPT)
was the first-line therapy. If unsuccessful despite at least 2
attempts or if thrombus fragmentation was identified,
additional small aspiration catheters or adjunctive throm-
bectomy devices were used.
Because the neurointerventionists at our institution have
been using this method primarily rather than stent retrievers,
a direct comparison of the 2 techniques at our institution
would be unfair and poorly powered in the stent retriever
arm. Therefore, we compared our results to published
series on stent retrievers by other experienced authors.7,8
Successful reperfusion was defined by postprocedure
TICI flow of grade 2b or 3. Good functional outcome was
defined as an mRS score of 0-2 at discharge. Symptomatic
intracerebral hemorrhage (sICH) was defined as hematoma
associated with a worsening NIHSS score of 4 points or
more.
The expected cost of the devices was totaled for each
case using market/list prices to eliminate the variability of
pricing among different institutions (a methodology that has
been used in other publications for device cost analysis)9
and compared with what the cost would have been for an
uncomplicated case using the Solitaire stent retriever device
(Covidien/ev3). Costs for the Penumbra system aspiration
cases included the cost of all reperfusion catheters (the
5MAX ACE plus any other adjunctive tools if required), 6
French long sheath (NeuronMAX), as well as coaxial
delivery catheters (3MAX or Velocity), canister, and aspira-
tion tubing. Costs for the Solitaire stent retriever cases used
as first-line therapy included the cost of balloon guide
catheter, microcatheter, and stent retriever (as recommend-
ed by parent company). Using device list prices, price
estimates for comparison are shown in Table 1. Sheaths,
microwires, diagnostic catheters, and closure devices were
not included in the cost analysis as they are used in the
same fashion for both techniques. As noted, the costs
shown in Table 1 are the expected costs based on list
prices. For the purposes of analysis in this study, however,
we used our average cost for each procedure, and the
procedures’ total average costs differ slightly from the total
expected costs.
The data obtained were compared with previously
published data: the Multicenter Randomized Clinical Trial
of Endovascular Treatment for Acute Ischemic Stroke in the
Netherlands (MR CLEAN)7 and the North American Solitaire
Stent Retriever Acute Stroke (NASA) Registry.8 The effect of
successful revascularization on length of stay was com-
pared using the Tukey honest significant difference (HSD)
test.
RESULTS
Demographics
A total of 31 patients were included in our study. All were
treated with the 5MAX ACE catheter as the primary tool for
mechanical thrombectomy. The patients’ mean age was
66.3 years – 17.8, and their mean admission NIHSS score
was 19.4 – 5.7 (Table 2). The target occlusion was located
in the proximal middle cerebral artery in 24 (77.4%) patients,
in the internal carotid artery in 6 (19.4%) patients, and in the
basilar artery in 1 (3.2%) patient. Eleven (35.5%) patients
had received intravenous recombinant tissue plasminogen
activator.
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TICI grade 2b-3 reperfusion was achieved in 26 (83.9%)
patients, while TICI grade 3 was attained in 19 (61.3%)
patients. Of the 83.9% of patients who achieved TICI grade
2b-3, successful revascularization by aspiration with the
Penumbra system was performed in 84.6% (22/26) of the
patients.
In a further breakdown of devices used to achieve TICI
grade 2b-3, 73.1% (19/26) of patients achieved reperfusion
with ADAPT and the 5MAX ACE catheter alone, 15.4% (4/26)
of patients required the addition of a separator or smaller
aspiration catheter, and 11.5% (3/26) of patients required
the addition of a stent retriever.
Overall, rescue therapy was used in 35.5% (11/31) of the
patient cohort. In one case, rescue therapy was used when
the 5MAX ACE could not be advanced past the ophthalmic
segment of the internal carotid artery to reach the thrombus.
The rescue techniques used were the Penumbra separator
(n¼5), smaller aspiration catheters (n¼6), and stent retriev-
ers (n¼5). Some cases required more than one rescue
therapy tool. A noteworthy observation is that 7 of our first
15 cases required additional devices (rescue) compared to
only 4 in the last 16 cases, suggesting a short learning curve
for using this new device. In the 5 cases in which TICI grade
2b-3 was not achieved, rescue therapy with stent retrievers
was attempted in 2/5 (40%) of the cases, smaller aspiration
catheters were used in 2/5 (40%), and the last case was
aborted because of contrast extravasation during the
procedure.
The average time from groin puncture to TICI grade 2b-3
reperfusion was 40 minutes (Table 3). Good functional
outcome was reported in 19 (61.3%) patients. The mean
discharge mRS score was 2.3 – 1.8. Thirteen patients were
discharged to home (41.9%), 11 to rehabilitation (35.5%), 2 to
a nursing home (6.5%), 2 to a skilled nursing facility (6.5%),
and 1 to hospice (3.2%). One patient was transferred to
another institution (3.2%), and we were not able to obtain
information on the final discharge disposition. The transfer
was done at the request of the family so that the patient could
be cared for closer to their home. One (3.2%) patient died.
Table 1. Thrombectomy Options: Cost Comparison
Stent Retriever
Thrombectomy Devices Price
ADAPT
Thrombectomy
Devicesc
Price of the ADAPT
Procedure if
Velocity Is Used
Price of the ADAPT
Procedure if
3MAX Is Used
Cello balloon guide cathetera $1,100 5MAX ACE $2,490 $2,490
Marksman cathetera $1,100 NeuronMAX 088 $ 495 $ 495
Solitaire revascularization devicea $7,200 Velocity Microcatheter $1,090
Prowler or similar microcatheterb $ 750 3MAX Aspiration Catheter $1,690
MAX Aspiration Tubing $ 370 $ 370
MAX Canister $ 370 $ 370
Total $10,150 Total $4,815 $5,415
Note: Cost estimates are based on list pricing for devices recommended by the manufacturer for each procedure. Consequently, these costs are the
expected costs for the procedures. For the purposes of analysis in this study, however, we used our average cost for each procedure, and the average
cost differs slightly from the expected cost. ADAPT, A Direct Aspiration First Pass Technique.
aDevice manufactured by Covidien/ev3.
bDevice manufactured by Cordis Neurovascular/Johnson & Johnson.
cAll devices manufactured by Penumbra, Inc.
Table 2. Baseline Demographics of the Current Series vs the NASA Registry and MR CLEAN7,8
Variable
Current Series
(n¼31)
NASA Registry
(n¼354)
MR CLEAN
(n¼500)
Mean age – SD, years 66.3 – 17.8 67 – 15.2 65.8 (range, 54.4-76.0)
Left hemisphere 48.4% (15/31) N/R 48.9%
Target occlusion
Middle cerebral artery 77.4% (24/31) 56% 73.8%
Internal carotid artery 19.4% (6/31) 23.2% 25.7%
Basilar artery 3.2% (1/31) 10.2% 0%
Mean NIHSS score at admissiona 19.4 – 5.7 18.1 – 6.6 17 (range, 14-21)
Administered intravenous recombinant tissue plasminogen activator 35.5% (11/31) N/R 87.1%
MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; NASA, North American
Solitaire Stent Retriever Acute Stroke; N/R, not reported.
aThe National Institutes of Health Stroke Scale (NIHSS) is composed of 11 items, each of which scores a specific ability on a numerical scale, with 0
indicating normal function. Consequently, a higher score indicates some level of impairment. Individual scores are summed to calculate a total score. The
maximum possible score is 42, and the minimum score is 0.
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The average length of stay increased as the reperfusion
grade decreased: TICI grade 3 ¼ 5.7 – 3.65 days, TICI
grade 2b¼ 9.14 – 8.33 days, and TICI grade <2b¼ 15.8 –
11.32 days. These findings are statistically significant when
compared based on angiographic outcome using the Tukey
HSD test (TICI grade 2b-3 vs TICI grade <2b: 6.8 – 5.34
days vs 15.8 – 11.32 days, P<0.05).
Regarding procedure-related complications, 2 patients
experienced sICH (6.5%), and 1 patient suffered extravasa-
tion of contrast (3.2%). Procedure-related complications
were similar in all series: current series 9.7%; MR CLEAN
8.6%; NASA Registry 9.9% (the NASA Registry only reports
sICH as procedure-related complications).
Cost Comparison
Our average cost for aspiration with the 5MAX ACE alone
was $4,916. In contrast, our average cost when a stent
retriever is used as the primary device is $9,620, so
aspiration with the 5MAX ACE alone can save 49% in
potential costs. However, these average costs do not reflect
the increased cost of rescue therapy tools that are used in
approximately 26% of stent retriever cases according to the
NASA Registry.8 In our study, the average cost of all cases,
including all adjunctive devices, was $6,997 per patient.
Compared with the cost of using a stent retriever as primary
device, this average cost illustrates a potential savings of
approximately 26% (Figure).
DISCUSSION
This initial clinical experience supports considering the
use of the 5MAX ACE catheter as first-line therapy for large
vessel occlusion in acute ischemic stroke. Our analysis
suggests that direct aspiration with a large bore catheter first
using ADAPT6 may represent an important potential cost-
saving approach to vessel revascularization that in our
experience results in high rates of reperfusion with rapid
procedural times, enabling excellent clinical outcomes with
acceptable safety.
Regarding angiographic and technical outcomes, the
percentage of our patients showing reperfusion to TICI
grade 2b-3—83.9%—is higher than the percentages report-
ed in the NASA Registry (72.5%)8 and in the MR CLEAN
study (58.7%).7 Reperfusion to TICI grade 3 in 61.3% of our
patients is also higher than the rates reported in the NASA
Registry (40.2%) and MR CLEAN (24%) and is comparable
to a 2014 publication describing the ADAPT FAST technique
that achieved reperfusion to TICI grade 3 in 61% of subjects
treated with the 5MAX ACE catheter and 41% of those
treated with the 5MAX.10 We believe that the larger lumen of
the 5MAX ACE catheter may lead to higher TICI grade 3
rates compared with the 5MAX.
Our mean time to reperfusion of 40 minutes using the
5MAX ACE is similar to the report of 36 minutes published in
201410 for a study using a similar technique, while in the
NASA Registry,8 the average time to revascularization is
approximately 77 minutes using stent retrievers as first-line
therapy.
Good functional outcome (mRS score 2) was seen in
61.3% of our patients, a finding that compares favorably with
the 32.6% of patients with good functional outcomes
reported in MR CLEAN7 and the 42% in the NASA Registry.8
In our cohort, 24 (77.4%) patients were discharged to home
or rehabilitation, another indicator of a satisfactory outcome.
Our sICH rate of 6.5% is comparable to the 9.9% in the
Table 3. Study Results of the Current Series vs the NASA Registry and MR CLEAN7,8
Variable
Current Series
(n¼31)
NASA Registry
(n¼354)
MR CLEAN
(n¼500)
Mean time from groin puncture to reperfusion,
minutes 40 – 16 77 N/R
Mean time from arterial puncture to TICI grade 2b-3
reperfusion, minutesa 40 – 14 N/R N/R
Postprocedure TICI grade 2b-3a 83.9% (26/31) 72.5% 58.7%
Postprocedure TICI grade 3a 61.3% (19/31) 40.2% 24%
Overall rescue therapy 35.5% (11/31) 25.7% N/R
Adjunctive use of stent retrievers as rescue therapy 16.1% (5/31) N/R N/R
Mortality 3.2% (1/31) 30.2% 21%
Procedure-related complications 9.7% (3/31) N/R 8.6%
Symptomatic intracerebral hemorrhage 6.5% (2/31) 9.9% 7.7%
Extravasation 3.2% (1/31) N/R 0.9% (2/233)
Mean discharge modified Rankin Scale score – SDb 2.3 – 1.8 N/R N/R
Good functional outcome (modified Rankin Scale
score of 0-2 at discharge)b 61.3% (19/31) 42% (at 90 days) 32.6% (at 90 days)
MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; NASA, North American
Solitaire Stent Retriever Acute Stroke; N/R, not reported.
aThe Thrombolysis In Cerebral Infarction (TICI) grading system is a tool for determining the response to thrombolytic therapy for ischemic stroke. The
grades range from 0 (no perfusion) to 3 (complete perfusion). TICI subcategory grade 2b indicates complete filling of all of the expected vascular territory,
but the filling is slower than normal. TICI grade 2b-3 is widely regarded as a successful angiographic outcome.
bThemodified Rankin Scale is used to measure the degree of disability in carrying out daily activities for people who have had a stroke or have some other
neurological disability. The scale is scored from 0 (no disability) to 6 (death). Higher scores indicate greater disability.
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NASA Registry and the 7.7% in MR CLEAN.7,8 The death
rate in our group was 3.2% vs 30.2% in NASA registry and
21% in MR CLEAN.7,8
The purpose of the cost analysis is to provide a basic
understanding of the relative procedural device costs
between ADAPT using the 5MAX ACE catheter and stent
retrievers in practice. Hospital administrators are acutely
aware of device costs for procedures. Both endovascular
and open surgeons are being tasked to reduce costs and to
justify inclusion of new products, sometimes by omitting
other products, as in the authors’ experience.
We do not warrant that our cost analysis defines cost
effectiveness because such a determination requires a
complete evaluation of the patient’s care.11 However, device
costs are a major cost in the treatment of large vessel
occlusions and are the only costs that the interventionalist
may completely control.
A study by Turk et al provides support for our cost-saving
findings.11 In a single-center retrospective study of me-
chanical thrombectomy, the average device cost of $15,798
for a stent retriever (the Solitaire or Trevo) with local
aspiration was significantly higher than the $10,263 cost of
the traditional Penumbra system and the $7,421 cost for
ADAPT.11 Their data thus showed a 53% cost savings with
ADAPT compared to a stent retriever with local aspiration,
consistent with our data showing a potential 49% cost
savings with ADAPT. These investigators included all costs,
whereas we did not include the costs of wires, diagnostic
catheters, sheaths, or closure devices. In our study, the
potential cost savings for our institution was approximately
26% when we added all cases together, including all rescue
therapy costs, and compared the cost with the cost of
successful revascularization with a stent retriever as the only
tool. If we consider that rescue therapy is required in at least
26% of stent retriever cases,8 the cost savings could be
much greater than our estimate.
Despite our small sample size, our data show that good
angiographic results correlate with shorter length of stay.
Shorter hospitalizations have the potential to produce
additional cost savings in the treatment of large vessel
occlusion strokes. The authors believe that improvement in
cerebral perfusion—not the actual device that was used to
perform the successful thrombectomy—reduces length of
stay.
One limitation of this study is the lack of a comparison
group of stent retriever cases performed at the same
institution. Because the current protocol shared by the 2
neurointerventionalists is to start with ADAPT, stent retriev-
ers are used primarily for smaller arteries, for tortuous
anatomy, and as rescue therapy following thromboaspira-
tion. Another limitation is the lack of blinded core laboratory
adjudication of angiographic endpoints; a metaanalysis of
trial data on angiographic evaluation of aneurysms has
shown that local centers may overestimate their results.12
Furthermore, our study is limited to a single center, which
makes the results potentially less generalizable, and the
data analysis is retrospective rather than prospective. While
the sample size is small compared to the data emerging
from multicenter randomized controlled trials, this report of
a relatively new device shows the potential for important
cost savings while maintaining a high degree of clinical
effectiveness. Although the preponderance of currently
available trial data is based on stent retrievers, the authors
believe that ADAPT deserves continued consideration as
first-line therapy and should be studied further with a
randomized, prospective cost-benefit analysis to guide
future recommendations for acute stroke care.
Figure. Comparison of average costs for aspiration with the 5MAX ACE alone vs the 5MAX ACE
plus adjunctive devices when needed vs the use of a stent retriever as first-line therapy.
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CONCLUSION
This single-center retrospective review of mechanical
thrombectomy cases using the large bore 5MAX ACE
catheter and ADAPT suggests that it should be considered
as a first-line approach for treatment for large vessel
occlusions. This technique resulted in high rates of
successful reperfusion, rapid reperfusion times, and excel-
lent clinical outcomes with important potential cost savings
compared to the first-line use of stent retrievers.
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